title: Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML.
abstract: We report the long-term follow up of 49 patients (pts) enrolled on plerixafor compassionate use protocol. Thirty-seven pts (76%) had failed one previous mobilization attempt, while 12 (24%) had failed two or more previous attempts. Using the combination of plerixafor and granulocyte colony-stimulating factor, we collected2.5 × 10(6) CD34+cells/kg in 33 pts (67%). Forty-three of the 49 pts proceeded to an auto-SCT (ASCT). The median days to WBC and platelet engraftment were 11 (range, 9-13 days) and 16 (range, 11-77 days) days post ASCT, respectively. The median WBC count, Hb and platelet counts 1 year after ASCT were 4.7 × 10(9)/L, 12.2 g/dL and 109 × 10(9)/L, respectively. With median follow up of 42 months (range <1-54 months), 21 pts had evidence of disease progression. Five pts developed myelodysplastic syndrome (MDS)/AML at median of 29 months post ASCT. The cumulative incidence of MDS/AML at 42 months was 17% (95% confidence interval, 6 to 32%). Development of secondary MDS/AML in pts proceeding to ASCT after plerixafor mobilization needs to be studied further in a larger cohort.
authors.affiliation: Blood and Marrow SCT Program, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA. deola@karmanos.org
authors.forename: A
authors.initials: A
authors.lastname: Deol
authors.forename: J
authors.initials: J
authors.lastname: Abrams
authors.forename: A
authors.initials: A
authors.lastname: Masood
authors.forename: Z
authors.initials: Z
authors.lastname: Al-Kadhimi
authors.forename: M H
authors.initials: MH
authors.lastname: Abidi
authors.forename: L
authors.initials: L
authors.lastname: Ayash
authors.forename: L G
authors.initials: LG
authors.lastname: Lum
authors.forename: V
authors.initials: V
authors.lastname: Ratanatharathorn
authors.forename: J P
authors.initials: JP
authors.lastname: Uberti
mesh_terms: D000328:Adult; D000368:Aged; D001596:Benzylamines; D057176:Compassionate Use Trials; D000080027:Cyclams; D005260:Female; D005500:Follow-Up Studies; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects; D006571:Heterocyclic Compounds / Q000008:administration & dosage*; D006801:Humans; D015994:Incidence; D015470:Leukemia, Myeloid, Acute / Q000209:etiology* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000209:etiology* / Q000276:immunology; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000276:immunology; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; C088327:plerixafor